Levosert Intrauterine Contraceptive Device - Experience of Introduction in a Nurse Led Clinic in a UK District General Hospital
ESC Congress Library. Dickins D. May 10, 2018; 208174; ESC273
Dr. Dyan Dickins
Dr. Dyan Dickins
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Levosert is a new Intrauterine contraceptive device marketed by Gedeon Richter in the UK. It contains levonorgestrel 52mg released at 20mcg/day for 3 years. The inserter and insertion technique is different to previously used levonorgestrel containing intra-uterine devices. We performed a prospective analysis of the inroduction of this device during its first 3 months of use in our nurse led contraceptive clinic at Arrowe Park Hospital in the UK. The analysis covered qualatitive aspects such as ease of insertion and patient pain scores during and immediately after insertion.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings